(Q38307574)

2 September 2017

1 reference

title

Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency (English)

1 reference

hyperlipoproteinemia type I

2 September 2017

main subject

1 reference

1 reference

1 reference

1 reference

1

Lesley J Scott

1 reference

2 September 2017

publication date

1 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

75

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

175-182

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0339-9

2 September 2017

exact match

0 references

cites work

Gene therapy for lipoprotein lipase deficiency

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

New lipid-lowering drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Gene therapy for lipoprotein lipase deficiency: working toward clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

A largely random AAV integration profile after LPLD gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

CD8(+) T-cell responses to adeno-associated virus capsid in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0339-9

Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon

21 January 2018

1 reference

12 December 2020

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression

1 reference

12 December 2020

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions

1 reference

12 December 2020

Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency

1 reference

12 December 2020

Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.

1 reference

12 December 2020

Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients

1 reference

12 December 2020

Association between pancreatitis and subsequent risk of pancreatic cancer: a systematic review of epidemiological studies

1 reference

12 December 2020

10.1007/S40265-014-0339-9

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1018653556

0 references

1 reference